Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

FDA Approvals, News & Updates

Tecvayli Received FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma

Rezlidhia FDA Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation

Adcetris Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma

Elahere FDA Approved for Patients with FRα-Positive, Platinum-Resistant Ovarian Cancer

Imjudo plus Imfinzi and Chemotherapy FDA Approved for Patients with Metastatic Lung Cancer

Libtayo plus Chemotherapy Now FDA Approved for Advanced Lung Cancer without Genomic Alterations

Imjudo New Immunotherapy FDA Approved with Imfinzi Immunotherapy for Patients with Liver Cancer

Enhertu First Drug Approved for Patients with HER2-Low Breast Cancer

Nubeqa Approved for Men with Metastatic Hormone-Sensitive Prostate Cancer

Pemazyre Approved for Patients with FGFR1-Positive Myeloid/Lymphoid Neoplasms

Page 1 of 16